Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984023 | 0.94 | PTGS2 (0.36) | PTGS2SIGMAR1SCN9ACNR2CCKBR | |
| SCHEMBL6500868 | 0.88 | PTGS2 (0.33) | PTGS2SCN9A | |
| SCHEMBL6490137 | 0.83 | PTGS2 (0.38) | PTGS2SIGMAR1KCNH2SCN9ACNR2 | |
| SCHEMBL6489101 | 0.73 | CNR2 (0.31) | CNR2 | |
| SCHEMBL6064596 | 0.67 | ALDH1A1 (0.37) | SCN9ACNR2CCKBRHSD11B1 | |
| SCHEMBL6065524 | 0.66 | CNR2 (0.37) | SCN9ACNR2CCKBR | |
| SCHEMBL6487195 | 0.60 | SLC16A3 (0.38) | CNR2 | |
| SCHEMBL6500948 | 0.59 | PARP1 (0.30) | — | |
| SCHEMBL6330166 | 0.58 | CCKBR (0.41) | SCN9ACCKBR | |
| SCHEMBL6489013 | 0.58 | CCKBR (0.33) | CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956053-B2 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | THE JAMES BLACK FOUNDATION LIMITED (GB) | 2005-10-18 | — | — | US | disclosed |
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | JAMES BLACK FOUNDATION LIMITED, THE (GB) | 2003-11-06 | — | — | US | disclosed |
| WO-2001090078-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKIN IN RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | CCKBR, GRPR, CCKAR | PTGS2 1270/4885SIGMAR1 248/4885KCNH2 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.